开发治疗性癌症疫苗：战场笔记
Creating therapeutic cancer vaccines: notes from the battlefield.
作者信息
Overwijk W W, Restifo N P
出版信息
Trends Immunol. 2001 Jan;22(1):5-7. doi: 10.1016/s1471-4906(00)01793-2.
Abstract
With the identification of tumor antigens and a knowledge of how to vaccinate against them, the field of tumor immunology faces new challenges. In this article, the authors argue that successful immunotherapies of the future will activate anti-tumor T cells without inducing their anergy or apoptotic death.
摘要
随着肿瘤抗原的鉴定以及如何针对这些抗原进行疫苗接种的知识的掌握，肿瘤免疫学领域面临着新的挑战。在本文中，作者认为未来成功的免疫疗法将激活抗肿瘤T细胞，而不会诱导其无反应性或凋亡死亡。
相似文献
1
Creating therapeutic cancer vaccines: notes from the battlefield.开发治疗性癌症疫苗：战场笔记
Trends Immunol. 2001 Jan;22(1):5-7. doi: 10.1016/s1471-4906(00)01793-2.
2
Tumor escape from the immune response: a major hurdle for successful immunotherapy of cancer?肿瘤逃避免疫反应：癌症成功免疫治疗的主要障碍？
Tunis Med. 2005 Dec;83 Suppl 12:7-10.
3
Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?肿瘤免疫逃逸：癌症成功免疫治疗的最后一道障碍？
Cancer Immunol Immunother. 1999 Oct;48(7):343-5. doi: 10.1007/s002620050584.
4
[Immune tolerance and active suppression in oncology. Immunological principles and therapeutic options].[肿瘤学中的免疫耐受与主动抑制。免疫学原理与治疗选择]
Chirurg. 2002 Mar;73(3):255-61. doi: 10.1007/s00104-001-0407-z.
5
Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer.基因改造肿瘤疫苗：打破宿主对癌症耐受性的障碍赛。
Expert Opin Biol Ther. 2001 Mar;1(2):193-204. doi: 10.1517/14712598.1.2.193.
6
"Tumor immunology meets oncology (TIMO) VI" from 7th to 8th of May 2010 in Halle, Germany.2010年5月7日至8日在德国哈雷举办的“肿瘤免疫学与肿瘤学会议（TIMO）第六届会议” 。
Cancer Immunol Immunother. 2011 Feb;60(2):299-303. doi: 10.1007/s00262-010-0912-3. Epub 2010 Aug 28.
7
Making and circumventing tolerance to cancer.诱导和规避癌症耐受性
Eur J Immunol. 2009 Sep;39(9):2345-53. doi: 10.1002/eji.200939612.
8
Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?作为打破免疫耐受用于临床的异种治疗性癌症疫苗：用还是不用？
Vaccine. 2014 Jul 7;32(32):4015-24. doi: 10.1016/j.vaccine.2014.05.006. Epub 2014 May 14.
9
Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved.个体化新生抗原肿瘤疫苗：尚未完全铺就的道路。
Cancer Immunol Res. 2020 Dec;8(12):1465-1469. doi: 10.1158/2326-6066.CIR-20-0526.
10
[Immunotherapy of cancer].[癌症的免疫疗法]
Ugeskr Laeger. 2002 Jun 3;164(23):3008-16.
引用本文的文献
1
The Neuroprotective Role of A2A Adenosine Purinoceptor Modulation as a Strategy Against Glioblastoma.A2A 腺苷嘌呤受体调节作为一种抗胶质母细胞瘤策略的神经保护作用
Brain Sci. 2024 Dec 21;14(12):1286. doi: 10.3390/brainsci14121286.
2
Adenosine Targeting as a New Strategy to Decrease Glioblastoma Aggressiveness.靶向腺苷作为降低胶质母细胞瘤侵袭性的新策略。
Cancers (Basel). 2022 Aug 20;14(16):4032. doi: 10.3390/cancers14164032.
3
Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.使用新型肿瘤特异性细胞毒性T细胞的胰腺癌特异性免疫疗法。
Oncotarget. 2016 Dec 13;7(50):83601-83610. doi: 10.18632/oncotarget.13469.
4
Potent Antitumor Activity Generated by a Novel Tumor Specific Cytotoxic T Cell.一种新型肿瘤特异性细胞毒性T细胞产生的强大抗肿瘤活性。
PLoS One. 2013 Jun 18;8(6):e66659. doi: 10.1371/journal.pone.0066659. Print 2013.
5
Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses.用于促进肿瘤特异性 CTL 反应的条件性超强 CTL 配体。
J Immunol. 2010 Jun 1;184(11):6514-21. doi: 10.4049/jimmunol.0900448. Epub 2010 May 7.
6
Adenosine receptors and cancer.腺苷受体与癌症。
Handb Exp Pharmacol. 2009(193):399-441. doi: 10.1007/978-3-540-89615-9_14.
7
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.白细胞介素-23作为癌症疫苗佐剂的免疫及抗肿瘤作用
J Immunol. 2006 May 1;176(9):5213-22. doi: 10.4049/jimmunol.176.9.5213.
8
Immunotherapy for lymphomas.淋巴瘤的免疫疗法。
Int J Hematol. 2003 Jun;77(5):444-55. doi: 10.1007/BF02986612.
9
Cancer vaccines: progress reveals new complexities.癌症疫苗：进展揭示了新的复杂性。
J Clin Invest. 2002 Aug;110(3):289-94. doi: 10.1172/JCI16216.
本文引用的文献
1
Contemporary analysis of MHC-related immunodominance hierarchies in the CD8+ T cell response to influenza A viruses.甲型流感病毒CD8+ T细胞应答中与主要组织相容性复合体（MHC）相关的免疫显性等级的当代分析。
J Immunol. 2000 Sep 1;165(5):2404-9. doi: 10.4049/jimmunol.165.5.2404.
2
Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.用呈递源自黑素瘤相关抗原MART-1和gp100的表位的树突状细胞对转移性黑素瘤患者进行1期免疫研究。
J Immunother. 2000 Jul-Aug;23(4):487-98. doi: 10.1097/00002371-200007000-00013.
3
Regulatory T cells: key controllers of immunologic self-tolerance.调节性T细胞：免疫自我耐受的关键调控者。
Cell. 2000 May 26;101(5):455-8. doi: 10.1016/s0092-8674(00)80856-9.
4
Regulatory T cells in autoimmmunity*.自身免疫中的调节性T细胞*。
Annu Rev Immunol. 2000;18:423-49. doi: 10.1146/annurev.immunol.18.1.423.
5
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.并非如此简单：重新评估免疫豁免和肿瘤逃逸机制。
Nat Med. 2000 May;6(5):493-5. doi: 10.1038/74955.
6
Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.用肿瘤细胞-树突状细胞杂交瘤进行疫苗接种后人类转移性肾细胞癌的消退
Nat Med. 2000 Mar;6(3):332-6. doi: 10.1038/73193.
7
Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.123例黑色素瘤患者的肿瘤浸润性T淋巴细胞对与主要HLA - A等位基因相关的共享黑色素瘤抗原的识别。
J Immunother. 2000 Jan;23(1):17-27. doi: 10.1097/00002371-200001000-00004.
8
Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.前沿：CD4 + T细胞对CD8 + T细胞针对模型肿瘤抗原反应性的调控
J Immunol. 2000 Jan 15;164(2):562-5. doi: 10.4049/jimmunol.164.2.562.
9
TCR-Mediated internalization of peptide-MHC complexes acquired by T cells.T细胞介导的T细胞所获得的肽-MHC复合物的内化作用。
Science. 1999 Oct 29;286(5441):952-4. doi: 10.1126/science.286.5441.952.
Zotero 插件